{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:39:54Z","timestamp":1790393994601,"version":"4.1.0"},"reference-count":27,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,30]]},"DOI":"10.18632\/oncotarget.11025","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T03:10:37Z","timestamp":1470193837000},"page":"56241-56252","source":"Crossref","is-referenced-by-count":23,"title":["The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib"],"prefix":"10.18632","volume":"7","author":[{"given":"Takanobu","family":"Morishita","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Otsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Iwase","sequence":"additional","affiliation":[{"name":"Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Imoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1078-0432.CCR-13-0052","article-title":"Sequential inhibitor therapy in CML:simulation elucidates the pattern of resistance mutations after second- and third-line treatment","volume":"19","author":"von Bubnoff","year":"2013","journal-title":"Clinical cancer research"},{"key":"2","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","article-title":"Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993","volume":"113","author":"Wiernik","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12185-013-1442-5","article-title":"The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission","volume":"98","author":"Hu","year":"2013","journal-title":"International Journal of Hematology"},{"key":"4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Estrov","year":"2012","journal-title":"Nature"},{"key":"5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Hazlehurst","year":"2008","journal-title":"Molecular cancer therapeutics"},{"key":"7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"Duyster","year":"2002","journal-title":"The Lancet"},{"key":"8","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","article-title":"Cancer cell lines for drug discovery and development","volume":"74","author":"Bodmer","year":"2014","journal-title":"Cancer research"},{"key":"9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/neuonc\/nos061","article-title":"Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma","volume":"14","author":"Li","year":"2012","journal-title":"Neuro-oncology"},{"key":"10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"Welm","year":"2011","journal-title":"Nature medicine"},{"key":"11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Dick","year":"1997","journal-title":"Nature medicine"},{"key":"12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1349-7006.2009.01440.x","article-title":"Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD\/SCID\/IL-2Rgammac\u2212\/\u2212 mice","volume":"101","author":"Naoe","year":"2010","journal-title":"Cancer science"},{"key":"13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Sidransky","year":"2011","journal-title":"Molecular cancer therapeutics"},{"key":"14","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1038\/bcj.2011.16","article-title":"The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells","volume":"1","author":"Naoe","year":"2011","journal-title":"Blood cancer journal"},{"key":"15","doi-asserted-by":"crossref","first-page":"13054","DOI":"10.1038\/srep13054","article-title":"Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells","volume":"5","author":"Naoe","year":"2015","journal-title":"Scientific reports"},{"key":"16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10637-010-9441-3","article-title":"Ascorbate\/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. Anandmechanistic study","volume":"29","author":"Verrax","year":"2011","journal-title":"Invest New Drugs"},{"key":"17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Sawyers","year":"2006","journal-title":"N Engl J Med"},{"key":"18","first-page":"1748","article-title":"Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines","volume":"39","author":"Kaplan","year":"1979","journal-title":"Cancer research"},{"key":"19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/bjc.2014.95","article-title":"Phase I\/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer","volume":"110","author":"Pereira","year":"2014","journal-title":"British journal of cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-012-2146-x","article-title":"Beyond radiation therapy: photodynamic therapy maintains structural integrity of irradiated healthy and metastatically involved vertebrae in a pre-clinicalmodel","volume":"135","author":"Whyne","year":"2012","journal-title":"Breast cancer research and treatment"},{"key":"21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0145-2126(90)90128-V","article-title":"Preferential uptake of benzoporphyrin derivative by leukemicnormal cells","volume":"14","author":"Levy","year":"1990","journal-title":"Leukemia research"},{"key":"22","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1038\/onc.2008.334","article-title":"TTK\/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress","volume":"27","author":"Yoshida","year":"2008","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1038\/sj.onc.1208953","article-title":"c-Abl regulates early growth response protein (EGR1) in response to oxidative stress","volume":"24","author":"Yuan","year":"2005","journal-title":"Oncogene"},{"key":"24","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","article-title":"Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance","volume":"107","author":"Kaufmann","year":"2006","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V77.11.2463.2463","article-title":"Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice","volume":"77","author":"Santoli","year":"1991","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Furukawa","year":"2001","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:59:24Z","timestamp":1589281164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":27,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,8,30]]}},"alternative-id":["11025","27494842"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11025","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}